2015
DOI: 10.1080/21645515.2015.1069448
|View full text |Cite
|
Sign up to set email alerts
|

Immune response to Hepatitis B vaccine in patients with celiac disease: A systematic review and meta-analysis

Abstract: These authors equally contributed to this work.

Help me understand this report

Search citation statements

Order By: Relevance

Paper Sections

Select...
2
1
1
1

Citation Types

0
16
0

Year Published

2017
2017
2024
2024

Publication Types

Select...
9

Relationship

0
9

Authors

Journals

citations
Cited by 25 publications
(16 citation statements)
references
References 28 publications
0
16
0
Order By: Relevance
“…The role of interferons in mucosal permeability is supported by studies where the occurrence of CD was observed during the course of hepatitis C treatment with interferon [59,61]. As for HBV-related chronic liver disease, a metanalysis of retrospective and prospective studies found that CD patients have lower rate of protective HBV antibodies [in the retrospective studies relative risk (RR): 0.732, 95%CI: 0.664-0.808; in the prospective studies, RR: 0.777, 95%CI: 0.629-0.960] [62]. However, the lack of randomized, controlled trials and the low number of participantsmaking it difficult to draw definitive conclusions -were acknowledged by the authors of this analysis.…”
Section: Viral Infectionsmentioning
confidence: 99%
“…The role of interferons in mucosal permeability is supported by studies where the occurrence of CD was observed during the course of hepatitis C treatment with interferon [59,61]. As for HBV-related chronic liver disease, a metanalysis of retrospective and prospective studies found that CD patients have lower rate of protective HBV antibodies [in the retrospective studies relative risk (RR): 0.732, 95%CI: 0.664-0.808; in the prospective studies, RR: 0.777, 95%CI: 0.629-0.960] [62]. However, the lack of randomized, controlled trials and the low number of participantsmaking it difficult to draw definitive conclusions -were acknowledged by the authors of this analysis.…”
Section: Viral Infectionsmentioning
confidence: 99%
“…Several studies have reported lower efficacy of anti-HBV vaccines in individuals with CD[ 176 , 177 ] , which has been confirmed by a recent meta-analysis[ 178 ]. Therefore, novel immunization strategies have been proposed to ensure complete protection in such cases; these strategies include higher doses of vaccine and/or additional injection and intramuscular or preferably intradermal administration of booster doses of HBV vaccine because direct administration into the skin can activate an immune response mediated by dendritic cells through lower doses of antigen as opposed to intramuscular route of administration, which acts on cellular immune response.…”
Section: Hepatitis Bmentioning
confidence: 76%
“…Lack of response has been correlated with age, smoking, obesity, male gender, and the presence of specific HLA molecules, including HLA-DQ2, DR3, and DR7 [ 25 ]. A 2015 meta-analysis [ 10 ] concluded that CD patients had a significantly lower rate of protective antibody response to HBV vaccination than healthy controls. An evaluation of the response to HBV should be implemented as a routine assessment in newly diagnosed patients who had previously been vaccinated [ 11 ].…”
Section: Vaccination Immunogenicitymentioning
confidence: 99%
“…Scientific interest in this topic arose in the 1970s, when early papers reported a large variety of immunological abnormalities in patients with CD [ 7 , 8 , 9 ]. Numerous clinical trials, meta-analyses and systematic reviews have since been conducted to better investigate the link between CD and vaccination [ 10 , 11 , 12 ]. However, a comprehensive vaccination program for CD patients is still missing.…”
Section: Introductionmentioning
confidence: 99%